Crinetics shareholders approve Vertex merger, closing expected September 1
Specialty pharma's consolidation cycle produced a clean result on August 28. Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) brought its pending merger with Vertex Pharmaceuticals Incorporated to a shareholder vote, and the margin…
Key takeaways
- Crinetics Pharmaceuticals shareholders approved its merger with Vertex Pharmaceuticals on August 28, 2026, with 79,240,098 votes for, 13,618 against, and 10,915 abstaining.
- The approval satisfied the final outstanding condition to closing, and the transaction is expected to close on or about September 1, 2026.
- Under the July 6, 2026 agreement, Vertex subsidiary Clark Merger Sub, Inc. will merge into Crinetics, which survives as a wholly owned Vertex subsidiary.
- A separate advisory, non-binding vote on merger-related executive compensation did not pass (44,803,403 against versus 33,854,149 for), but it placed no condition on closing.
- Crinetics brings two named assets to Vertex: PALSONIFY for acromegaly and atumelnant, in development for congenital adrenal hyperplasia.
Specialty pharma's consolidation cycle produced a clean result on August 28. Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) brought its pending merger with Vertex Pharmaceuticals Incorporated to a shareholder vote, and the margin left little to interpret: 79,240,098 votes for adoption of the merger agreement, 13,618 against, and 10,915 abstaining, with 79,264,631 of 106,095,205 eligible shares represented. The approval satisfies what Crinetics described as the final outstanding condition to closing, and the company anticipates the transaction will close on or about September 1, 2026.
The structure of the vote
The merger agreement, dated July 6, 2026, calls for Vertex's wholly owned subsidiary Clark Merger Sub, Inc. to merge with and into Crinetics, a Delaware corporation headquartered at 6055 Lusk Boulevard in San Diego, California. Crinetics survives that step as a wholly owned Vertex subsidiary. The special meeting was called under a definitive proxy statement filed with the SEC on July 31, 2026, with a record date of July 27, 2026.
A second item on the agenda, an advisory and non-binding vote on executive compensation tied to the merger, did not carry. Shareholders voted 44,803,403 against and 33,854,149 for, with 607,079 abstentions. A third proposal to adjourn the meeting was never put to shareholders because the merger vote passed with votes to spare. The advisory character of the compensation measure places no condition on closing.
What moves to Vertex
Crinetics brings two named assets into the transaction. PALSONIFY targets acromegaly, and atumelnant is in development for congenital adrenal hyperplasia. Vertex's forward-looking materials anticipated that the combined business could generate more than $5 billion in annual revenue, that the transaction would become accretive to non-GAAP operating income in 2029, and that it would support sustained double-digit revenue growth. Vertex attached conditional framing to each of those figures, and all remain subject to the risks identified in company disclosures.
Vertex has described its deal financing as fully committed bridge financing. For a transaction of this structure, committed capital removes a material variable from the days before close. CRNX is set to exit the Nasdaq Global Select Market as an independent company on or around September 1.
Related reading
Source · 來源